AI-generated summary
The authors retrospectively compared upadacitinib plus 308 nm excimer light, upadacitinib alone, and 308 nm excimer light alone in patients with progressing facial vitiligo, using VASI and DLQI scores. The combination group's VASI fell from 0.875 to 0.23 by week 20, and the authors report it was significantly superior to the other groups, with one patient experiencing manageable acne exacerbation.
- Who or what was studied
- Patients with progressing facial vitiligo who had been treated with upadacitinib, 308 nm excimer light, or both, in a retrospective analysis
- Wavelengths
- 308 nm
- Limits stated in the abstract
- The abstract describes a retrospective analysis with no stated sample size, and it does not state group sizes or a control design, so the findings are limited in certainty.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 308 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Statistical significance. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.